Travere Therapeutics, Inc. 8-K

What Happened
On May 4, 2026, Travere Therapeutics, Inc. (NASDAQ: TVTX) filed a Form 8‑K (Item 2.02) and issued a press release announcing its financial results for the quarter ended March 31, 2026. The press release and accompanying information were attached to the 8‑K as Exhibit 99.1. The report was signed by CEO Eric Dube on May 4, 2026.

Key Details

• Filing date: May 4, 2026 (Form 8‑K, Item 2.02).
• Reporting period: Quarter ended March 31, 2026.
• Press release attached as Exhibit 99.1 to the 8‑K.
• Interactive XBRL cover page provided as Exhibit 104; 8‑K signed by CEO Eric Dube.

Why It Matters
This 8‑K signals Travere’s routine quarterly earnings disclosure (earnings, revenue, quarterly results). The filing itself notes the press release is the source of the results—investors should read Exhibit 99.1 for revenue, profit/loss, cash position, and any guidance or management commentary. Because the 8‑K does not duplicate full financial statements in-line here, check the attached press release and subsequent SEC filings (10‑Q) or the company’s investor relations page for detailed figures and context before making investment decisions.